Phase 2
N=10
Effect of Increasing Doses of Tiopronin on Cystine Capacity in Patients With Cystinuria
Cystinuria
Bottom Line
View on ClinicalTrials.gov: NCT03663855 ↗Enrolled (actual)
10
Serious AEs
0.0%
Results posted
Dec 2021
Primary outcome: Primary: Change in Cystine Capacity From Baseline — -63.6; 76; 53.4; 103.1 mg/L
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Tiopronin (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- NYU Langone Health
- Primary completion
- Sep 2019
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Cystine Capacity From Baseline |
-63.6; 76; 53.4; 103.1 | — |
Summary
The purpose of this study is to determine the minimum effective dose of the cysteine binding thiol drug (CBTD) Tiopronin on urine cystine capacity, which is a measure of cystine solubility in the urine, in patients with cystinuria to evaluate the effect of escalating doses of cystine binding thiol drugs on the cystine capacity of the urine. The overall goal will be to help guide therapy and ultimately minimize unnecessary side effects caused by larger dosages.
Cystinuria is a rare genetic disease that can lead to significant morbidity in affected patients due to the recurrent nature of the disease. This study will follow the levels of urine cystine capacity in order to help guide treatment and to use lower than usually prescribed Tiopronin doses to decrease the potential side effects while maintaining therapeutic benefit. This will increase adherence with the medications by decreasing the burden of the large number of pills that need to be taken daily.
Eligibility Criteria
Inclusion Criteria
- Patients with a confirmed laboratory diagnosis of cystinuria who meet the following criteria: (1) stone analysis demonstrating cystine as a component, or (2) increased urinary cystine excretion (>250mg/24hrs in adults).
- A medical regimen that includes Tiopronin.
- Willing to use a medically accepted form of birth control, if female and of child bearing- potential
- Ability to reliably urinate in a collection vessel and measure urine volume.
- Ability to give informed consent.
- Documentation of a stable complete blood count (CBC) and urinalysis (UA) in the six month period prior to the date of enrollment.
- Enrollment in Rare Kidney Stone Consortium (RKSC) Protocol 6401 (Cystinuria Registry)
Exclusion Criteria
- Women who are pregnant, breastfeeding, or trying to become pregnant
- Patients with renal colic
- Patients who are scheduled to undergo a surgical procedure
- Inability to give informed consent
Data sourced from ClinicalTrials.gov (NCT03663855). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.